Onco-Innovations Advances Cancer Nanomedicine with Lead Drug Candidate ONC010

Cancer nanomedicine is emerging from an early period of skepticism, with more than 20 approved formulations now improving therapeutic index and patient quality of life during treatment. The field has evolved from a theoretical concept to a practical approach that addresses the fundamental trade-off in chemotherapy: the same drugs that kill cancer cells can damage healthy tissue, limiting dosing and reducing quality of life. By packaging drugs in nanoscale carriers, these formulations keep more drug in circulation long enough to accumulate in tumors while reducing unnecessary exposure in healthy tissue.

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is a Canadian oncology company developing inhibitors of Polynucleotide Kinase Phosphatase (PNKP), an enzyme central to repairing DNA strand breaks. Blocking PNKP is designed to leave cancer cells unable to repair damage caused by chemotherapy or radiation. The company's lead drug candidate, ONC010, pairs a small-molecule PNKP inhibitor with a polymer nanodelivery system designed to extend circulation, increase drug retention in tumors, and improve tolerability.

Recent manufacturing updates point to a sharpening focus on scalability, reproducibility, and regulatory readiness ahead of first-in-human studies. The company has achieved kilogram-scale precursor production and proposed a collaboration with Nanosoft Polymers to further refine the nanodelivery platform. These developments are critical for moving from preclinical research to clinical trials, where consistent and scalable manufacturing is essential.

The importance of this announcement lies in the potential of ONC010 to address key challenges in cancer treatment. By targeting PNKP, a novel mechanism, and using a nanodelivery system to enhance drug delivery, Onco-Innovations aims to improve the therapeutic index of chemotherapy, potentially allowing higher doses with fewer side effects. As the nanomedicine field continues to mature, companies like Onco-Innovations are working to define what the next generation of cancer therapies looks like.

For more information on Onco-Innovations, visit the company's newsroom at https://nnw.fm/ONNVF. This press release was disseminated by NetworkNewsWire, a specialized communications platform. More details are available at https://www.NetworkNewsWire.com.